Announcements
May 1, 2024
Mayo Clinic Laboratories and Progentec Diagnostics Launch Lupus Advanced Biomarker Testing Services
ROCHESTER, Minn. and OKLAHOMA CITY, Oklahoma. As a successful outcome of the collaboration announced in 2023 between Mayo Clinic Laboratories, a leading global reference laboratory, and Progentec Diagnostics, a digital health and biomarker technology-based company focused on autoimmune conditions, Progentec’s proprietary biomarker blood tests for the proactive management of systemic lupus erythematosus are available. These tests, known as the DX Lupus Disease Activity Index and the DX Lupus Flare Risk Index, are accessible to all clients of Mayo Clinic Laboratories effective April 25 for managing active disease and anticipating the onset of symptoms.
"These two tests signify the significant progress our two organizations have made in bringing new diagnostic and monitoring options to patients and their physicians," says William Morice II, M.D., Ph.D., CEO of Mayo Clinic Laboratories. "With our ongoing commitment to collaboration and innovation, we're dedicated to advancing the field of diagnostics and enhancing patient care."
"Progentec is committed to offering advanced diagnostic and monitoring options to physicians within the Mayo Clinic Laboratories ecosystem. We are excited to collaborate with Mayo Clinic Laboratories to expand the availability of these technologies and make a difference to lupus patients and their health," says Mohan Purushothaman, Ph.D., CEO of Progentec Diagnostics.
Learn more here
November 7, 2023
Mayo Clinic Laboratories and Progentec® collaborate to bring advanced biomarker testing services to patients with autoimmune diseases
ROCHESTER, Minn. and OKLAHOMA CITY, Oklahoma. Mayo Clinic Laboratories, a leading global reference laboratory, and Progentec Diagnostics, a digital health and biomarker technology-based company focused on autoimmune conditions, today announced a strategic collaboration to bring Progentec’s suite of proprietary biomarker blood tests for the proactive management of autoimmune diseases to market. The collaboration aims to increase accessibility for providers and patients across the U.S. and select global markets.
"Progentec’s understanding of the immunologic foundations, combined with Mayo Clinic Laboratories' expertise as a world leader in lab services, provides hope for a significant unmet need for patients," says William Morice II, M.D., Ph.D., CEO of Mayo Clinic Laboratories. “Additionally, the collaboration will facilitate Mayo Clinic experts to provide guidance on ways to enhance test adoption and promote appropriate use."
Additionally, Mary Jo Williamson, chief administrative officer, Mayo Clinic Laboratories, has joined the Progentec board of directors. Ms. Williamson oversees the Mayo Clinic diagnostic business lines, which include Mayo Clinic Laboratories and Remote Diagnostics. With over 30 years of experience in healthcare, Ms. Williamson will bring a wealth of insight to the board.
"The work represents a significant step forward in our mission to provide robust testing services that contribute to the health and well-being of individuals and communities with autoimmune conditions," says Mohan Purushothaman, Ph.D., CEO of Progentec Diagnostics. "It also establishes a sound framework for new tests under development for autoimmune conditions."
Mayo Clinic has a financial interest in the technology referenced in this press release. Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education and research.
About Mayo Clinic Laboratories
Mayo Clinic Laboratories, the global leader in turning test results into clinical answers, provides advanced testing and pathology services for 3,400 healthcare organizations in partnership with Mayo Clinic's Department of Laboratory Medicine and Pathology. Mayo Clinic Laboratories offers more than 4,400 tests and pathology services and performs more than 26 million tests annually. Revenue is used to support medical education and research at Mayo Clinic.
About Progentec
Progentec Diagnostics, Inc. is a digital health and diagnostic company focused on improving outcomes in patients with autoimmune disease, a family of complex chronic conditions that account for $150B in annual healthcare spend in the U.S. The company has brought together a suite of novel biomarker blood tests with advanced AI-based technologies that use cytokine and digital signals to provide predictive power leading to better care decisions and improved patient quality of life. Integration of digital and virtual solutions to ensure continuity of care is a major area of focus for the company.
Contact:
Mayo Clinic: newsbureau@mayo.edu
Progentec Diagnostics: corpcomms@progentec.com
Learn more here
March 21, 2023
Progentec Launches PROACTIVE™ - A Novel Approach to Screen and Diagnose Lupus at an Early Stage
Progentec, a leader in next-gen diagnostics and digital technologies for the management of autoimmune diseases, announced today the launch of PROACTIVE™, a collaborative study with GSK aimed at identifying individuals at risk of developing lupus and guiding them through a virtual diagnostic journey. Lupus is a chronic autoimmune disease that affects millions of people worldwide, and early detection and diagnosis are crucial for effective treatment and management. The PROACTIVE™ study aims to empower individuals to take control of their health by providing them with a comprehensive and personalized approach to help them evaluate their symptoms..
Learn more here
September 27, 2022
Progentec Diagnostics announces Appointment of Healthcare Industry Executive Marc Jones to its Board of Directors
Progentec, a leader in next-gen diagnostics and digital technologies for the management of autoimmune diseases, announced today that Marc Jones, seasoned healthcare industry executive, has joined Progentec's Board of Directors. Jones has a demonstrated track record of providing reliable executive leadership within dynamic, fast-paced corporate environments in both public and high-growth, venture-backed private companies.
Learn more here
June 8, 2021
Progentec Announces Research Collaboration with GSK to Assess Proteomics and Digital Health Tools for Lupus (SLE) Care
"For too long, precision medicine has been a buzzword when it comes to caring for Lupus Warriors," said Mohan Purushothaman, Ph.D., Chairman and CEO of Progentec. "This research has the potential to show how both immunological data and patient-generated data can support clinicians as they identify the optimal treatment for each lupus patient."
Learn more here
April 2020
Launch of the OASIS Study, a digital lupus study
Progentec will begin enrolling participants into the OASIS study soon. Participants will use the LupusCorner® Research app, a 21 CFR Part-11-compliant data capture tool built using the FDA's open source MyStudies codebase.
Learn more here.
January 2020
Progentec Raises $5M in Series A Funding
In a round led by Plains Venture Partners, Progentec raised $5M to commercialize the aiSLE DX Lupus Flare Prediction Test, release the aiSLE DX Lupus Classification/Diagnosis Test, and launch research into digital biomarkers. Learn more here.
News stories & press releases
21 March 2023
Progentec Launches PROACTIVE™ - A Novel Approach to Screen and Diagnose Lupus at an Early Stage
Progentec Diagnostics, a leader in diagnostic and digital technologies for management of autoimmune diseases, announced today the launch of PROACTIVE™, a collaborative study with GSK aimed at identifying individuals at risk of developing lupus and guiding them through a virtual diagnostic journey. Lupus is a chronic autoimmune disease that affects millions of people worldwide, and early detection and diagnosis are crucial for effective treatment and management. The PROACTIVE™ study aims to empower individuals to take control of their health by providing them with a comprehensive and personalized approach to help them evaluate their symptoms.
27 September 2022
Marc Jones, seasoned healthcare industry executive, has joined Progentec's Board of Directors. Jones has a demonstrated track record of providing reliable executive leadership within dynamic, fast-paced corporate environments in both public and high-growth, venture-backed private companies. His wealth of experience and knowledge will support Progentec in its mission to improve health outcomes for people living with autoimmune diseases.
9 June 2021
GlaxoSmithKline taps Progentec to bring AI, wearable tech to lupus treatments
On a mission to reduce those difficulties and help lupus patients take a more proactive stance toward managing the condition are GlaxoSmithKline and Progentec Diagnostics. The pair formed a research partnership to study the use of various digital tools and technologies in predicting flare-ups and tracking the disease's progression.
8 April 2021
Bendcare Supports aiSLE™ DX Flare Risk Index Testing Access for Patients with Lupus (SLE)
"aiSLE™ DX Flare Risk Index represents a paradigm shift in the treatment of lupus (SLE) patients. Proteomics empowers clinicians to treat lupus patients based on changes in the underlying immunology," said Mohan Purushothaman, Ph.D., Chairman and CEO of Progentec.
2 Februrary 2021
Progentec Launches Care Management Platform for Lupus (SLE) Patients and Clinicians
aiSLE™ MGMT is a comprehensive disease management platform that combines biomarkers and digital care delivery. aiSLE™ MGMT transforms immunological and digital data into clinical reports, and provides patients with access to a health coach and lupus care tools via a mobile app.
21 Sept 2020
Progentec’s Novel Blood Test Predicts Lupus Flares Up to 12 Weeks Before They Occur
The aiSLE™ DX Flare Risk Index is a laboratory test that measures the blood-based biomarkers that are measurably altered before the onset of flare symptoms in lupus patients. Early research measured 52 soluble immune mediators, including cytokines and chemokines, in plasma before disease flares. Studies of patient samples have allowed that panel to be reduced to 11 biomarkers.
13 July 2020
Progentec Signs Agreements to Develop, Commercialize MS Technologies
“The use of blood-based laboratory tests for the measurement of multiple sclerosis disease progression offer an opportunity for clinicians to intervene more proactively to increased disease activity, potentially limiting the brain damage experienced by patients,” said Mohan Purushothaman, president and CEO of Progentec
27 June 2020
LupusCorner Identified as a 2020 Top Lupus Blog by Healthline
One of the most challenging aspects of living with lupus is the lack of understanding surrounding this complex autoimmune disorder. In choosing the year’s best lupus blogs, we looked for sites that are raising awareness and creating communities that inspire and empower.
3 June 2020
Hakan Sakul, Ph.D., Vice President and Head of Diagnostics at Pfizer, has joined the Progentec Board of Directors. Dr. Sakul has a distinguished track record in the development and commercialization of companion diagnostics, precision medicine, and pharmacogenomics.
21 April 2020
Progentec Readies Launch of Digital Lupus Research Study
"OASIS is a 100% remote clinical research study. Participants can sign up online and complete the study without ever visiting a clinician," said Eldon Jupe, Ph.D. This study will further Progentec's efforts to develop digital biomarkers for the prediction of lupus flares and the measurement of disease activity.
8 January 2020
Progentec Raises $5M in Series A Funding Led by Plains Venture Partners
"With these funds we will be able to realize our vision of providing a comprehensive solution for management of lupus patients that combines proprietary blood biomarkers with high levels of sensitivity and specificity with continuous remote digital monitoring to benefit millions of lupus patients world-wide," said Progentec's CEO, Mohan Purushothaman.
6 October 2019
Company aims to radically improve lupus cares
“The patient comes first,” said Mohan Purushothaman, Ph.D., president and CEO of Progentec. “Our platform is carefully crafted to help people with lupus at every step of the patient journey. From identification and diagnosis to symptom and medication management, Progentec offers people with lupus the right tool at the right moment to take charge of their health.”
1 August 2019
Federal Agency Grants Award to Fast Track Research of New Lupus Disease Activity Measurement Tests
The National Institute of Allergy and Infectious Diseases, a division of the National Institutes of Health, has awarded a Fast-Track Small Business Innovation Research grant to Progentec to research the accuracy and predictive power of blood biomarker tests as a tool for measuring systemic lupus erythematosus disease activity. The tests could potentially support clinicians in selecting optimal treatment plans, adjusting medication dosing and measuring outcomes for people with lupus.
31 July 2019
Progentec Granted $1.7M to Validate Measure of SLE Disease Activity
The grant will be used to validate the biomarkers and methods used in Progentec’s disease activity test, called aiSLE DX – Disease Activity Index. The project will be led by Melissa Munroe, MD, PhD, and Eldon Jupe, PhD. The test is expected to be available by the end of 2019.
30 July 2019
Progentec Diagnostics, Inc. and Karate Health, Inc. announced today that they have merged, offering laboratory testing and digital technologies for the diagnosis and management of lupus (SLE), multiple sclerosis (MS), and other autoimmune diseases.
25 July 2019
Progentec ... today announced it has been awarded a Fast-Track Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID). The grant funds will be released in two installments starting with a Phase I award of $225,000. In total, the grant has the potential to provide $1.7 million in non-dilutive financial resources.
4 May 2019
OKC-Based Progentec Diagnostics Refines Test to Predict Future Lupus Flares
Research developed by Munroe and her collaborator, fellow OMRF scientist Judith James, M.D., Ph.D., ... led them to develop an algorithm that can predict lupus disease flares up to three months in advance. The pair examined immune proteins in the blood of hundreds of lupus patients with support from the National Institutes of Health’s Autoimmunity Centers of Excellence.
14 April 2019
Progentec Diagnostics Raises Funds to Support Advances in Lupus Detection and Management
Diagnostics innovator Progentec Diagnostics Inc, Oklahoma City, recently completed a second round of funding co-led by i2E and Chicago-based OCA Ventures. NMC Lifesciences, a leading global healthcare provider, also participated in the round.
January 2019
Progentec Diagnostics Brings in LupusCorner
Progentec also simultaneously announced the acquisition of LupusCorner, a leading patient-empowerment platform for people with systemic lupus erythematosus (SLE) and lupus nephritis. By integrating LupusCorner’s technology platform and data insights, Progentec says it is positioned to develop a first-in-class lupus-management platform.
1 November 2018
Progentec Raises Funds to Support Advances in Lupus Detection & Acquires LupusCorner
Progentec ... today announced the completion of a second round of funding co-led by i2E and Chicago-based OCA Ventures. The funding will help bring Progentec's tool for identifying lupus flare ups and a biomarker-based disease-activity index closer to commercialization.
29 November 2017
Progentec Obtains Financing to Continue Refining Tools for Predicting Lupus Flares
Progentec Diagnostics is closer to marketing a new set of tools for predicting lupus flares after obtaining $1.25 million in financing. Progentec is collaborating with Dr. Judith James, a lupus researcher who developed the technology, to refine the platform.
27 November 2017
New tools for predicting lupus flares now one step closer to market
Progentec Diagnostics, Inc. has completed first round financing of $1.25 million. The ability to predict an impending flare represents significant value to lupus patients and their physicians. This test is currently not available and is a focus area for us,” said Sanjiv Sharma, Chairman of Progentec.
26 November 2017
Scott Meacham: Entrepreneurs, startups and organizations that support them deserve our thanks
This year it’s been an across-the-board drive as i2E has closed a typical year’s worth of investments since August while helping portfolio companies clear the significant milestones that contribute to creating the groundbreaking exits of the future — companies that include Progentec Diagnostics, a startup working to provide a breakthrough diagnostic test that enables physicians to better manage the complicated and damaging autoimmune disease of lupus.
30 September 2015
OMRF and Progentec collaborate to commercialize new autoimmue diagnostic